University of Bath
Bath, Somerset, BA2 7AY, United Kingdom
NCT Number: NCT06068803
The goal of this randomised, double-blinded, placebo-controlled trial is to investigate the immune, metabolic and cognitive effects of four weeks of daily ketone supplementation in adults aged 60 to 80 with stable health. The main objectives are to assess the effects of the intervention versus placebo on markers of metabolic health, inflammation, immune function, adipose tissue, and cognitive performance.
Participants will undergo two weeks of baseline monitoring followed by a four-week supplementation period in which they will drink a ketone monoester drink or taste-matched placebo three times a day. During these periods, participants will record their diet and supplement intake and their physical activity and blood glucose will be monitored using wearable devices. At the beginning and end of the supplementation period, participants will undergo testing in the university physiology laboratories, involving blood, expired air and adipose tissue samples, as well as cognitive tests, physical tests and questionnaires.
Looking for future studies?
Notify Me60 year–80 year
All sexes
Interventional
Not applicable
Bath, Somerset, BA2 7AY, United Kingdom
Background: Research shows that ketones have beneficial effects on metabolism, inflammation and brain health in humans. In mice, they have also been shown to influence pathways involved in ageing. Ketones are natural molecules that are produced by the body when people fast (abstain from eating) for longer than 16-24 hours or eat a diet low in carbohydrates. It is now possible to consume ketones in the form of a drink.
Aims: This study aims to investigate if consuming a ketone drink for four weeks improves immunometabolic and cognitive health in adults aged 60 to 80 years. The main objectives are to assess the effects of the intervention versus placebo on:
Methods: The study is a randomised, double-blinded, placebo-controlled trial. Thirty participants (male and female) aged 60 to 80 years old with stable health will be recruited. Participants will undergo two weeks of baseline monitoring followed by a four-week supplementation period in which they will drink a ketone monoester drink or placebo three times a day. During these periods, participants will record their diet and supplement intake and their physical activity and blood glucose will be monitored using wearable devices. For two days in the supplementation period, participants will replicate their food consumption and physical activity so that they match two days in the baseline period (these are known as matched meal and activity days).
At the beginning and end of the supplementation period, participants will come to the physiology laboratories at the University of Bath for testing. Here, measures will be taken of their body weight, body composition, blood pressure, cognitive function and physical function, as well as samples of expired air, fat tissue and blood for analysis. Sleep and quality of life will be assessed via questionnaires.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
Other names: D-β-hydroxybutyrate-R 1,3-Butanediol
Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
Time frame: 1 day during baseline period and 1 day during the intervention period
Glucose control will be measured using a continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in 24h average glucose AUC will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity.
Time frame: 1 day during baseline period and 1 day during the intervention period
Glucose control will be measured using continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in glycemic variability will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity.
Time frame: Pre (day 0) and post (day 29)
Measured in fasting blood sample by automated analyser (Daytona Rx)
Time frame: Pre (day 0) and post (day 29)
Measured in fasting blood sample by automated analyser (Daytona Rx)
Time frame: Pre (day 0) and post (day 29)
Measured in fasting blood sample by automated analyser (Daytona Rx)
Time frame: Pre (day 0) and post (day 29)
Measured in fasting blood sample by automated analyser (Daytona Rx)
Time frame: Pre (day 0) and post (day 29)
Measured in fasting blood sample using a high-sensitivity human insulin enzyme-like immunosorbent assay (ELISA)
Time frame: Pre (day 0) and post (day 29)
Calculated from fasting plasma insulin and fasting plasma glucose
Time frame: Pre (day 0) and post (day 29)
Calculated from fasting plasma insulin and fasting plasma FFA
Time frame: Pre (day 0) and post (day 29)
Measured using a digital body weight scales
Time frame: Pre (day 0) and post (day 29)
Measured using a measurement tape
Time frame: Pre (day 0) and post (day 29)
Calculated from waist and hip circumferences
Time frame: Pre (day 0) and post (day 29)
Assessed by Dual Energy X-ray Absorptiometry (DEXA) scan
Time frame: Pre (day 0) and post (day 29)
Assessed by calf peripheral Quantitative Computed Tomography (pQCT)
Time frame: Pre (day 0) and post (day 29)
Measured using an automated blood pressure device. Both systolic and diastolic blood pressure will be measured
Time frame: Pre (day 0) and post (day 29)
Key inflammatory cytokines including CRP will be quantified by R-plex, U-plex and V-plex kits on a Mesoscale QuickPlex SQ120
Time frame: Pre (day 0) and post (day 29)
Peripheral blood mononuclear cells (PBMCs) isolated from whole blood will be incubated with fluorophore-conjugated antibodies and analysed with a flow cytometer to examine the phenotype and cytokine production of immune cells
Time frame: Pre (day 0) and post (day 29)
Adipose tissue stromal vascular fraction (SVF) will be incubated with fluorophore-conjugated antibodies and analysed with a flow cytometer to examine the phenotype and cytokine production of immune cells
Time frame: Pre (day 0) and post (day 29)
Adipose tissue explants will be cultured ex vivo for 3h. Concentrations of key adipokines and cytokines in supernatant will be quantified by R-plex, U-plex and V-plex kits on a Mesoscale QuickPlex SQ120
Time frame: Pre (day 0) and post (day 29)
Whole-tissue RNAseq
Time frame: Pre (day 0) and post (day 29)
This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the number of correct symbols within the allowed time. Higher is better.
Time frame: Pre (day 0) and post (day 29)
This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the number of correct responses and the response latency. Higher is better.
Time frame: Pre (day 0) and post (day 29)
This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the time taken to complete trails A and B. Lower is better.
Time frame: Pre (day 0) and post (day 29)
This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the maximum number of digits recalled correctly. Higher is better.
Time frame: Pre (day 0) and post (day 29)
The test will be administered by a trained researcher.
Time frame: Pre (day 0) and post (day 29)
Physical activity will be assessed using a combined accelerometer and heart rate monitor (Actiheart) worn throughout the baseline period and weeks 3 and 4 of the intervention period
Time frame: Pre (day 0) and post (day 29)
Heart rate will be assessed using an accelerometer (Actiheart) worn throughout the baseline period and weeks 3 and 4 of the intervention period
Time frame: Pre (day 0) and post (day 29)
Questionnaire to assess sleep quality
Time frame: Pre (day 0) and post (day 29)
Questionnaire to assess health-related quality of life
Time frame: Pre (day 0) and post (day 29)
Standard set of tests to measure physical function in elderly involving gait speed, chair stand and balance test
Time frame: Post (day 29)
Acceptability of the supplement will be assessed via questionnaire using a 7-point Likert scale
Time frame: Pre (day 0) and post (day 29)
Adipose tissue protein expression will be assessed by targeted immunoblotting.
University of Bath
Other
Investigating the Immunometabolic and Cognitive Effects of 4 Weeks of Ketone Supplementation in Older Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05732909
Acid-Base Imbalance, Acidosis
Aarhus, Aarhus N, Denmark
View Trial DetailsNCT06203392
Acid-Base Imbalance, Acidosis
Gainesville, Florida, United States
View Trial DetailsNCT03814304
Accidental Falls, Aging
Roslindale, Massachusetts, United States
View Trial DetailsNCT05866393
Aging, Behavior
Cleveland, Ohio, United States
View Trial Details